Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown alveolar soft part sarcoma predicted - sensitive Crizotinib Crizotinib Phase II Actionable In a Phase II trial, Xalkori (crizotinib) treatment resulted in partial response (PR) in 2.5% (1/40) and stable disease (SD) in 87.5% (35/40) of patients with TFE3-rearranged, MET-positive alveolar soft part sarcoma, with a 1-year progression-free survival (PFS) rate of 37.5%, and resulted in PR in 25% (1/4) and SD in 75% (3/4) of patients without TFE3 rearrangement and MET expression, with a 1-year PFS rate of 50% (PMID: 29216400; NCT01524926). 29216400
Unknown unknown sarcoma not applicable IGF-1R Inhibitor Conatumumab + Ganitumab Phase Ib/II Actionable In a Phase Ib/II trial, Ganitumab and Conatumumab (AMG 655) combination treatment resulted in stable disease in 33% (5/15) of patients with sarcoma, including one with leiomyosarcoma (PMID: 24816908). 24816908
Unknown unknown ovarian cancer not applicable IGF-1R Inhibitor Conatumumab + Ganitumab Phase Ib/II Actionable In a Phase Ib/II clinical trial, Ganitumab and Conatumumab combination treatment resulted in stable disease in 56% (5/9) of patients with ovarian cancer (PMID: 24816908). 24816908
Unknown unknown colorectal cancer not applicable IGF-1R Inhibitor Conatumumab + Ganitumab Phase Ib/II Actionable In a Phase Ib/II clinical trial, Ganitumab and Conatumumab combination treatment resulted in one unconfirmed partial response and stable disease in 38% (6/16) of patients with colorectal cancer (PMID: 24816908). 24816908
Unknown unknown Advanced Solid Tumor not applicable IGF-1R Inhibitor Conatumumab + Ganitumab Phase Ib/II Actionable In a Phase Ib/II trial, Ganitumab and Conatumumab (AMG 655) combination treatment resulted in stable disease in 36% (28/78) of patients with an advanced solid tumor (PMID: 24816908). 24816908
Unknown unknown pancreatic cancer not applicable IGF-1R Inhibitor Conatumumab + Ganitumab Phase Ib/II Actionable In a Phase Ib/II clinical trial, Ganitumab and Conatumumab combination treatment resulted in stable disease in one patient out of sixteen with pancreatic cancer (PMID: 24816908). 24816908
Unknown unknown non-small cell lung carcinoma not applicable IGF-1R Inhibitor Conatumumab + Ganitumab Phase Ib/II Actionable In a Phase Ib/II clinical trial, Ganitumab and Conatumumab combination treatment resulted in stable disease in 50% (11/22) of patients with non-small cell lung carcinoma (PMID: 24816908). 24816908
Unknown unknown sarcoma not applicable IGF-1R Inhibitor Ganitumab Phase II Actionable In a Phase II trial, Ganitumab treatment resulted in a 6% (2/35) partial response and stable disease in 49% (17/35) of patients with metastatic Ewing's family of tumors or desmoplastic small round cell tumor (PMID: 22508822). 22508822
Unknown unknown Advanced Solid Tumor not applicable IGF-1R Inhibitor Ganitumab Phase I Actionable In a Phase I trial, Ganitumab (AMG 479) demonstrated safety and preliminary efficacy in patients with advanced solid tumors (J Clin Oncol (Meeting Abstracts) 2007 25: 3002). detail...
Unknown unknown pancreatic adenocarcinoma not applicable IGF-1R Inhibitor GSK1904529A Preclinical - Cell line xenograft Actionable In a preclinical study, GSK1904529A treatment resulted in inhibition of tumor growth by 52% in xenograft models of pancreas adenocarcinoma (PMID: 19383820). 19383820
Unknown unknown Ewing sarcoma not applicable IGF-1R Inhibitor GSK1904529A Preclinical - Cell culture Actionable In a preclinical study, Ewing's sarcoma cells were sensitive to GSK1904529A in culture, resulting in decreased cell viability (PMID: 19383820). 19383820
Unknown unknown breast cancer not applicable IGF-1R Inhibitor GSK1904529A Preclinical - Cell culture Actionable In a preclinical study, GSK1904529A treatment resulted in decreased cell viability of breast cancer cells in culture (PMID: 19383820). 19383820
Unknown unknown multiple myeloma not applicable IGF-1R Inhibitor GSK1904529A Preclinical - Cell culture Actionable In a preclinical study, multiple myeloma cells were sensitive to GSK1904529A in culture, resulting in decreased cell viability (PMID: 19383820). 19383820
Unknown unknown non-small cell lung carcinoma not applicable IGF-1R Inhibitor AXL1717 Phase Ib/II Actionable In a Phase 1b/II trial, AXL1717 (picropodophyllin) was well tolerated and 25% (4/16) of patients diagnosed with NSCLC demonstrated a partial tumor response (PMID: 26161618). 26161618
Unknown unknown malignant glioma not applicable IGF-1R Inhibitor PQ401 Preclinical - Cell line xenograft Actionable In a preclinical study, PQ401 disrupted cell migration and inhibited growth of glioma cells in culture, and suppressed tumor growth in cell line xenograft models (PMID: 25971682). 25971682
Unknown unknown extraosseous Ewing's sarcoma not applicable IGF-1R Inhibitor GSK1838705A Preclinical Actionable In a preclinical study, multiple cancer cell lines including multiple myeloma and Ewing's sarcoma were sensitive to GSK1838705A (PMID: 19825801). 19825801
Unknown unknown glioblastoma multiforme not applicable IGF-1R Inhibitor GSK1838705A Preclinical - Cell line xenograft Actionable In a preclinical study, GSK1838705A inhibited cell growth and prevented tumor growth via apoptotic induction in glioma cells in both culture and xenograft models (PMID: 26238593). 26238593
Unknown unknown triple-receptor negative breast cancer not applicable IGF-1R Inhibitor KW-2450 Preclinical Actionable In a preclinical study, KW-2450 inhibited the growth of triple-negative breast cancer cells in culture and in xenograft models (PMID: 26443806). 26443806
Unknown unknown Advanced Solid Tumor not applicable IGF-1R Inhibitor KW-2450 Phase I Actionable In a Phase I trial, 40% (4/10) of patients with advanced solid tumors demonstrated stable disease when treated with KW-2450 (PMID: 26850678). 26850678
Unknown unknown breast cancer not applicable IGF-1R Inhibitor KW-2450 Preclinical Actionable In a preclinical study, KW-2450 inhibited growth of several breast cancer cell lines in culture, including ESR1 positive, ERBB2 (HER2) positive/ESR1 positive, ERBB2 (HER2) positive, and triple-negative subtypes (PMID: 26443806). 26443806
Unknown unknown triple-receptor negative breast cancer not applicable IGF-1R Inhibitor KW-2450 + Selumetinib Preclinical Actionable In a preclinical study, the combination of KW-2450 and Selumetinib worked synergistically to inhibit growth of triple-negative breast cancer cells in culture (PMID: 26443806). 26443806
Unknown unknown Advanced Solid Tumor not applicable IGF-1R Inhibitor XL228 Phase I Actionable In a Phase I trial, XL228 treatment resulted in stable disease for 12 weeks or longer in 31% (25/80) of patients with an advanced solid tumor and a partial response in one patient (J Clin Oncol 28:15s, 2010 (suppl; abstr 3105)). detail...
Unknown unknown non-small cell lung carcinoma not applicable IGF-1R Inhibitor XL228 Phase I Actionable In a Phase I clinical trial, 41% (9/22) of patients with an advanced solid tumor experienced stable disease for at least 12 weeks and a partial response response was reported in one patient with NSCLC when treated with XL228 (J Clin Oncol 28:15s, 2010 (suppl; abstr 3105)). detail...
Unknown unknown lung small cell carcinoma not applicable IGF-1R Inhibitor Etoposide + NVP-ADW742 Preclinical Actionable In a preclinical study, NVP-ADW742, when combined with Toposaur (etoposide), demonstrated a synergistic effect in small cell lung cancer cell lines, resulting in inhibition of Akt signaling (PMID: 15746061). 15746061
Unknown unknown osteosarcoma not applicable IGF-1R Inhibitor BMS-754807 Preclinical - Cell line xenograft Actionable In a preclinical study, BMS-754807 treatment resulted in significant tumor growth delay in 67% (4/6) of cell line xenograft models of osteosarcoma (PMID: 21298745). 21298745
Unknown unknown acute lymphocytic leukemia no benefit IGF-1R Inhibitor BMS-754807 Preclinical - Cell line xenograft Actionable In a preclinical study, BMS-754807 treatment resulted in no change in event-free survival in 100% (7/7) of cell ine xenograft models of acute lymphocytic leukemia (PMID: 21298745). 21298745
Unknown unknown rhabdomyosarcoma not applicable IGF-1R Inhibitor BMS-754807 Preclinical - Cell line xenograft Actionable In a preclinical study, BMS-754807 treatment resulted in significant tumor growth delay in 33% (2/6) of cell line xenograft models of rhabdomyosarcoma (PMID: 21298745). 21298745
Unknown unknown renal Wilms' tumor not applicable IGF-1R Inhibitor BMS-754807 Preclinical - Cell line xenograft Actionable In a preclinical study, BMS-754807 treatment resulted in significant tumor growth delay in 100% (3/3) of cell line xenograft models of Wilms tumor (PMID: 21298745). 21298745
Unknown unknown neuroblastoma not applicable IGF-1R Inhibitor BMS-754807 Preclinical - Cell line xenograft Actionable In a preclinical study, BMS-754807 treatment resulted in significant tumor growth delay in 67% (4/6) of cell line xenograft models of neuroblastoma (PMID: 21298745). 21298745
Unknown unknown rhabdoid cancer not applicable IGF-1R Inhibitor BMS-754807 Preclinical - Cell line xenograft Actionable In a preclinical study, BMS-754807 treatment resulted in significant tumor growth delay in 100% (3/3) of cell line xenograft models of rhabdoid tumor (PMID: 21298745). 21298745
Unknown unknown Ewing sarcoma not applicable IGF-1R Inhibitor BMS-754807 Preclinical - Cell line xenograft Actionable In a preclinical study, BMS-754807 treatment resulted in significant tumor growth delay in 50% (2/4) of cell line xenograft models of Ewing sarcoma (PMID: 21298745). 21298745
Unknown unknown oral squamous cell carcinoma not applicable IGF-1R Inhibitor TAE226 Preclinical - Cell line xenograft Actionable In a preclinical study, TAE226 treatment increased apoptosis and decreased proliferation and migration of oral squamous cell carcinoma cells in culture and inhibited tumor growth in cell line xenograft models (PMID: 22766511). 22766511
Unknown unknown Advanced Solid Tumor not applicable IGF-1R Inhibitor Linsitinib Phase I Actionable In a Phase I trial, Linsitinib (OSI-906) was well-tolerated and resulted in stable disease in 41% (27/66) of patients with an advanced solid tumor and a partial response in two patients with adrenocortical carcinoma (PMID: 25208878). 25208878
Unknown unknown adrenal cortex cancer not applicable IGF-1R Inhibitor Linsitinib Phase I Actionable In a Phase I trial, Linsitinib (OSI-906) was well-tolerated and resulted in stable disease in 41% (27/66) of patients with an advanced solid tumor and a partial response in two patients with adrenocortical carcinoma (PMID: 25208878). 25208878
Unknown unknown breast cancer not applicable Trk Receptor Inhibitor (Pan) Altiratinib Preclinical Actionable In a preclinical study, Altiratinib (DCC-0701) inhibited tumor growth and decreased lung metastasis in a mouse breast cancer model (PMID: 26285778). 26285778
Unknown unknown Advanced Solid Tumor not applicable Trk Receptor Inhibitor (Pan) DS6051b Phase I Actionable In a Phase I clinical trial, DS-6051b was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors (Cancer Res July 15 2016 (76) (14 Supplement) CT024). detail...
Unknown unknown neuroendocrine carcinoma sensitive Trk Receptor Inhibitor (Pan) DS6051b Phase I Actionable In a Phase I clinical trial, treatment with DS-6051b was well-tolerated in patients with advanced solid tumors, and resulted in partial responses in two patients, including a patient with neuroendocrine carcinoma (Cancer Res July 15 2016 (76) (14 Supplement) CT024). detail...
Unknown unknown Advanced Solid Tumor not applicable Trk Receptor Inhibitor (Pan) MGCD516 Phase I Actionable In a Phase I trial, MGCD516 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (J Clin Oncol 34, 2016 (suppl; abstr 2575)). detail...
Unknown unknown Advanced Solid Tumor not applicable Trk Receptor Inhibitor (Pan) MGCD516 Preclinical - Cell line xenograft Actionable In a preclinical study, MGCD516 decreased tumor cell proliferation, tumor vascularization, and target phosphorylation in a variety of human advanced solid tumor cell line xenograft models (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1, Abstract 930). detail...
Unknown unknown colorectal cancer not applicable Trk Receptor Inhibitor (Pan) MGCD516 Preclinical - Cell line xenograft Actionable In a preclinical study, MGCD516 decreased tumor cell proliferation, tumor vascularization, and target phosphorylation in human colorectal carcinoma cell line xenograft models (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1, Abstract 930). detail...
Unknown unknown glioblastoma multiforme not applicable Trk Receptor Inhibitor (Pan) MGCD516 Preclinical - Cell line xenograft Actionable In a preclinical study, MGCD516 decreased tumor cell proliferation, tumor vascularization, and target phosphorylation in human glioblastoma multiforme cell line xenograft models (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1, Abstract 930). detail...
Unknown unknown breast carcinoma not applicable Trk Receptor Inhibitor (Pan) MGCD516 Preclinical - Cell line xenograft Actionable In a preclinical study, MGCD516 decreased tumor cell proliferation, tumor vascularization, and target phosphorylation in human breast carcinoma cell line xenograft models (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1, Abstract 930). detail...
Unknown unknown lung carcinoma not applicable Trk Receptor Inhibitor (Pan) MGCD516 Preclinical - Cell line xenograft Actionable In a preclinical study, MGCD516 decreased tumor cell proliferation, tumor vascularization, and target phosphorylation in human lung carcinoma cell line xenograft models (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1, Abstract 930). detail...
Unknown unknown stomach carcinoma not applicable Trk Receptor Inhibitor (Pan) MGCD516 Preclinical - Cell line xenograft Actionable In a preclinical study, MGCD516 decreased tumor cell proliferation, tumor vascularization, and target phosphorylation in human stomach carcinoma cell line xenograft models (Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1, Abstract 930). detail...
Unknown unknown liposarcoma not applicable Trk Receptor Inhibitor (Pan) MGCD516 Preclinical - Cell line xenograft Actionable In a preclinical study, MGCD516 blocked cell proliferation of a human liposarcoma cell line in culture and repressed tumor growth in xenograft models (PMID: 26675259). 26675259
Unknown unknown pancreatic ductal adenocarcinoma not applicable Trk Receptor Inhibitor (Pan) Lestaurtinib Preclinical Actionable In preclinical studies, lestaurtinib has been shown to have an antitumor effect in xenograft models of pancreatic ductal adenocarcinoma (PMID: 10473107). 10473107
Unknown unknown non-small cell lung carcinoma not applicable Trk Receptor Inhibitor (Pan) Merestinib Preclinical Actionable In a preclinical study, LY2801653 inhibited tumor growth in mouse xenograft models of non-small cell lung cancer (PMID: 24305878). 24305878
Unknown unknown Advanced Solid Tumor not applicable Trk Receptor Inhibitor (Pan) Merestinib Phase I Actionable In a Phase I trial, LY2801653 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (Cancer Res October 1, 2014 74:CT237). detail...
Unknown unknown colorectal cancer not applicable Trk Receptor Inhibitor (Pan) Merestinib Phase I Actionable In a Phase I trial, LY2801653 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients with colorectal cancer (Cancer Res October 1, 2014 74:CT237). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02473497 Expanded access Crizotinib Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients Available